MNTA: Discounting Immediate Competition
My question is essentially what would the multiple look like in the absence of looming competition, whether or not that's realistic, with a favorable M-Copaxone outcome, et al?
Since MNTA is the first FoB, or biogeneric, there is no precedent. What is the multiple historically for a generic company with its first high-margin FDA approval?
For that matter, what is the P/E biotech norm for companies like MNTA if we exclude the 7/23 FDA approval of enoxaparin (i.e., a company with both generic and novel drugs in the pipeline)?
Market Data 
Markets 
AI
